Article
Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2024
Ben-Ammar Imen, Rousseau Adrien, Nicolle Rémy, Tarabay Anthony, Boige Valérie, Valery Marine, Pudlarz Thomas, Malka David, Gelli Maximiliano, Fernandez-De-Sevilla Elena, Fuerea Alina, Tanguy Marie-Laure, Rouleau Etienne, Barbe Rémy, Mathieu Jacques R R, Jaulin Fanny, Smolenschi Cristina, Hollebecque Antoine, Ducreux Michel, Boileve Alice
Abstract excerpt
BACKGROUND: KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC), and around 10% of patients harbor KRAS wild-type tumors (KRASWT). METHODS: A retrospective chart review of clinical/molecular data was performed including all PDAC patients with a determined KRAS status (tumor molecular profiling on tissue or liquid biopsy). RESULTS: 342 patients were included with 54 KRASWT...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.